HCPCS Code J2506: Injection, Pegfilgrastim, Excludes Biosimilar, 0.5 mg

Bill J2506 right. Read our documentation tips and learn about proper billing and modifier use to prevent pegfilgrastim denials.

Use Code

## **What is a pegfilgrastim injection?** HCPCS code J2506 is the specific code for originator pegfilgrastim, billed per 0.5 mg, and it excludes biosimilar products. Pegfilgrastim (for example, Neulasta) is a long-acting granulocyte colony stimulating factor used to reduce the risk of febrile neutropenia in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies. In clinical practice, pegfilgrastim supports neutrophil recovery during a chemotherapy cycle that involves myelosuppressive anti-cancer drugs or cytotoxic chemotherapy. It is not a diagnostic injection. Pegfilgrastim is administered by standard subcutaneous injection or by an on-body injector that delivers a timed subcutaneous injection the day after chemotherapy. The device application is reported separately and includes cannula insertion. Per prescribing information, pegfilgrastim is given at least 24 hours after chemotherapy and not within 14 days before chemotherapy. Use J2506 only for the originator product; biosimilar products have different Q-codes listed below. This article serves as a concise coding guide for accurate reporting and administration.

## **J2506 documentation requirements** Complete records help align the medical record with the claim. Here's what you should include: ### **Indication and diagnoses** Document the clinical indication, such as prophylaxis of febrile neutropenia in nonmyeloid malignancies. Link appropriate ICD-10-CM codes that support prophylaxis during chemotherapy. ### **Drug, dose, and units** Record the exact dose in milligrams and translate to HCPCS units, where 1 unit equals 0.5 mg. For example, 6 mg equals 12 units of J2506. Note the brand used to confirm originator pegfilgrastim rather than a biosimilar. ### **Route and device** State the administration route as subcutaneous injection or on-body injector. When using an on-body injector, document device placement and patient education, and reference the separate procedure code for application. ### **Timing within the chemotherapy cycle** Record the date and time of dosing relative to the most recent chemotherapy session. Include instructions that align with prescribing information for timing after cytotoxic chemotherapy. ### **Product details and tracking** Capture NDC, lot number, expiration date, and site of care. Maintain documentation for any product wastage and keep supporting invoices when required by the payer.

## **J2506 billing requirements** Align billing details with the medical record to avoid rework. Keep in mind the following: ### **Units per 0.5 mg** Bill one unit of J2506 for every 0.5 mg administered. Confirm that the billed units match the documented dose. ### **Wastage reporting** Use JW to report discarded drug from a single-dose container on a separate claim line. Use JZ to attest zero wastage when the entire container was administered. Medicare requires JW or JZ on applicable claims; the effective date for JZ use under Medicare was July 1, 2023. ### **Administration procedure coding** Report the drug administration separately. Use 96372 for standard subcutaneous injection. Use 96377 for the on-body injector application for timed subcutaneous injection; this code includes cannula insertion. ### **Claim essentials** Include the NDC when required, the total units, diagnosis codes, and the service date. Verify payer frequency edits and prior authorization requirements before dispensing. ### **Site-of-service and program rules** Confirm plan policy on outpatient hospital, physician office, or home settings. Ensure documentation and billing reflect the payer’s coverage rules for pegfilgrastim during a chemotherapy cycle.

## **J2506 applicable modifiers** Use only the modifiers your payer requires. 1. JW: Report discarded drug amount from single-dose containers on a separate claim line. 2. JZ: Report zero drug wastage when the entire single-dose container was administered. 3. JB: Some payers request this for subcutaneous administration to denote route. Confirm payer policy before use. 4. UD or U7: Program- or state-specific modifiers when directed by the payer.

## **Other relevant codes** Report related procedure codes and do not substitute biosimilar Q-codes for J2506. - **96372**: Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular. - **96377**: Application of on-body injector for timed subcutaneous injection; includes cannula insertion. - **Q5108**: Pegfilgrastim-jmdb (Fulphila) per 0.5 mg. - **Q5111**: Pegfilgrastim-cbqv (Udenyca) per 0.5 mg. - **Q5120**: Pegfilgrastim-bmez (Ziextenzo) per 0.5 mg. - **Q5122**: Pegfilgrastim-apgf (Nyvepria) per 0.5 mg. - **Q5127**: Pegfilgrastim-fpgk (Stimufend) per 0.5 mg. - **Q5130**: Pegfilgrastim-pbbk (Fylnetra) per 0.5 mg.

Frequently asked questions

J2505 describes pegfilgrastim 6 mg per dose, while J2506 is billed per 0.5 mg and is the specific code for originator pegfilgrastim that excludes biosimilar products. Many payers prefer J2506 for unit-based billing precision; use biosimilar Q-codes when a biosimilar is administered and follow payer policy for code selection.

Neulasta (originator pegfilgrastim) is billed with J2506 per 0.5 mg; some payers may still accept J2505 for a single 6 mg dose, so verify plan rules. Report the administration separately—96372 for a standard subcutaneous injection or 96377 when applying the on-body injector for a timed subcutaneous injection.

Use 96372 for the intramuscular administration of Invega Sustenna (paliperidone palmitate). Bill the drug supply with the HCPCS product code J2426 (injection, paliperidone palmitate, extended-release, per 1 mg) with units matching the dose.